{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-030277","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.720439+00:00","generated_at":"2026-06-22T08:43:35.088068+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xtant Medical Q3 2022 revenue $14.5M (+5% YoY); net loss widens to $2.4M","bullets":["Revenue of $14.5M, up 5% from $13.8M in Q3 2021, driven by 12% biologics growth from OsteoFactor and OsteoVive Plus launches.","Gross margin improved to 54.6% from 52.2% on better capacity utilization.","Net loss of $2.4M ($0.03 loss per share) vs. $1.8M ($0.02) in prior-year period.","Non-GAAP adjusted EBITDA loss of $0.9M, compared to $0.6M loss a year ago.","CEO cited recent $9.75M private placement to support growth and expects full operating capacity by Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-030277","json":"https://secwatch.observer/filing/0001493152-22-030277.json","markdown":"https://secwatch.observer/filing/0001493152-22-030277.md","text":"https://secwatch.observer/filing/0001493152-22-030277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315222030277/0001493152-22-030277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315222030277/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:43:35.088068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e7439067f44acb7040a689653c5c53badc7fec2","claim":"Xtant Medical Holdings, Inc. reported third quarter ended September 30, 2022 results: revenue $14.5 million, net income $2.4 million, EPS $0.03 per share.","evidence_excerpt":"by the first quarter of 2023 enabling our team to take advantage of the robust demand environment.” Third Quarter 2022 Financial Results Third quarter 2022 revenue was $14.5 million, compared to $13.8 million for the same quarter in 2021. The increase in revenue was largely attributable to introductions of new products. Gross margin for the third quarter of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315222030277/0001493152-22-030277-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$14.5 million"},{"label":"Net income","value":"$2.4 million"},{"label":"EPS","value":"$0.03 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}